IT Maximization for Population Health Management

Those of you who have been in the health-system setting for several decades have seen many changes. Some of the changes originate within the care setting, whereas many others are brought on by external circumstances. Even those who have been in health systems for only 5 years can recall a recent change in the organization that greatly impacted pharmacy. More change is coming. In this installment, we explore critical technology-related changes of which you should be aware.Health systems are increasingly finding themselves involved in something they describe as “straddling.” They are straddling current reimbursement drivers and practices while concurrently getting ready for population health strategies to replace what has been the norm for decades. We have been saying for years that we cannot imagine a scenario where we will use less technology in any foreseeable future. When it comes to operating a health system focused on managing populations, we cannot imagine anything more important than the effective use of the following top 5 technologies.     

浅谈大数据时代食品药品监管数据资源的综合管理

随着互联网和信息技术的不断发展,各行各业对数据的应用愈加重视,数据资源的重要价值随之突显;国家层面也陆续出台相关文件,对数据管理提出相应要求。本文通过问题和现状分析,着重研究探讨在食品药品监管系统内如何针对数据资源开展共建共享和统筹管理,以期能够为相关工作提供参考。     

How a Blockchain Approach Can Improve Data Reliability in the COVID-19 Pandemic

The rapid spread of COVID-19 made it necessary to quickly collect and share viral genomic sequences, sometimes making quantity prevail over the quality of information. Can research pay this price? Blockchain technology, based on the concept of a ledger that guarantees the authenticity and traceability of information, could be the best applicable solution.     

World Health Organization and Essential Medicines

In June 2017, the World Health Organization released 20th Model List of Essential Medicines for adults and sixth Model List of Essential Medicines for children. In our commentary, we describe the changes to the Essential Medicine list, and identify deficits in excluding medicines for management of diseases with a high burden. In using tracer conditions such as cardiovascular and thromboembolic disease, mental health, and diseases of the musculoskeletal system, we highlight the absence of several medicines, which are incorporated into major clinical practice guidelines. We recommend that the World Health Organization review its process with respect to identifying disease conditions as well as evidence-based therapies.     

大数据背景下对我国药品研发战略管理的思考

随着“互联网+战略”的持续深入推进以及信息技术的高速发展,大数据技术和观念已经逐步渗透到社会的各行各业。具体到药品研发领域,在药品研发过程中应用大数据技术进行管理,将会在极大程度上提高海量药品相关数据的筛选和管理效率,并为研发决策提供科学指引。本文以大数据和特点的分析为导入,着重分析了药品研发战略管理的核心以及大数据在其中的重要作用,并对大数据应用于我国药物研发战略管理提出了对策和建议。     

大数据在药物警戒中的应用研究进展

目的对国际上大数据技术在药物警戒中的应用和发展情况进行回顾总结,为完善我国药物警戒系统提供参考。方法对官方文件以及近几年来国内外相关文献中报道的大数据在药物警戒中的应用进行整理、分析与归纳,并以药物性肝损伤为案例进行分析。结果越来越多的国家逐步开始建立药物警戒的数据库、协作网络及联盟,其中大数据技术发挥了很大的作用,不仅用于药品不良事件的监测和分析,还可以形成辅助药物警戒的预测模型,对不良反应进行预警和防范。结论药物警戒的发展模式已经发生改变,未来大数据技术在药物警戒中的作用会更加显著,我国可以借鉴国际发展经验,积极探索适合我国的药物警戒发展道路。     

乡镇社区中青年血压异常人群健康管理的干预作用分析

目的对应用综合健康管理模式对出现血压异常的乡镇社区中青年人群实施干预的临床效果进行研究。方法抽取300例血压异常乡镇社区中青年人资料,将其分为对照组和干预组,平均每组150例。采用常规管理模式对对照组患者实施干预;在常规管理模式基础上,采用综合健康管理模式对干预组患者实施干预。结果干预组患者血压控制效果明显优于对照组;血压控制所需时间和接受干预时间明显短于对照组;出现并发症的人数明显少于对照组;对护理干预满意度明显高于对照组。结论应用综合健康管理模式对出现血压异常的乡镇社区中青年人群实施干预的临床效果非常明显。     

医学大数据在药物基因组学领域中的应用与发展

摘 要随着药物基因组学研究的不断发展,医学大数据在药物基因组学领域中的应用越来越多。本文从建立大型药物基因组学数据库、借助电子健康档案与基因分型数据库开展药物基因组学研究、创建可促进研究成果向临床转化的大型知识库三个方面,介绍了医学大数据在药物基因组学领域中的应用与发展方向。     

Co-operation — Can it be Done and How?

Abstract: The case for co-operation is presented along with that for confrontation. Recent encouraging developments in the detection and treatment of drug related problems need to take place in an environment calculated to reduce the incidence of those problems. A proposal to liberalise South Australia's licensing laws is instanced as a case for confrontation.     

Ochratoxin A Dietary Exposure of Ten Population Groups in the Czech Republic: Comparison with Data over the World

Ochratoxin A is a nephrotoxic and renal carcinogenic mycotoxin and is a common contaminant of various food commodities. Eighty six kinds of foodstuffs (1032 food samples) were collected in 2011–2013. High-performance liquid chromatography with fluorescence detection was used for ochratoxin A determination. Limit of quantification of the method varied between 0.01–0.2 μg/kg depending on the food matrices. The most exposed population is children aged 4–6 years old. Globally for this group, the maximum ochratoxin A dietary exposure for “average consumer” was estimated at 3.3 ng/kg bw/day (lower bound, considering the analytical values below the limit of quantification as 0) and 3.9 ng/kg bw/day (middle bound, considering the analytical values below the limit of quantification as 1/2 limit of quantification). Important sources of exposure for this latter group include grain-based products, confectionery, meat products and fruit juice. The dietary intake for “high consumers” in the group 4–6 years old was estimated from grains and grain-based products at 19.8 ng/kg bw/day (middle bound), from tea at 12.0 ng/kg bw/day (middle bound) and from confectionery at 6.5 ng/kg bw/day (middle bound). For men aged 18–59 years old beer was the main contributor with an intake of 2.60 ng/kg bw/day (“high consumers”, middle bound). Tea and grain-based products were identified to be the main contributors for dietary exposure in women aged 18–59 years old. Coffee and wine were identified as a higher contributor of the OTA intake in the population group of women aged 18–59 years old compared to the other population groups.     

大数据在疾病预防控制中的重要性

简述了大数据在传染性疾病和慢性疾病的预防控制的主要应用,分析了大数据在传染病疫情预警和控制、慢性疾病病因调查、预防治疗上的重要性,并针对大数据在疾病防控方面准确度不高、数据公开与隐私保护不足的缺点提出建议。